These observations are in agreement with the weaker ID in patients bearing mutations at EP300 compared to CREBBP [97-99] and with the different prevalences of mutations in each of these genes among RSTS patients. This evidence concerns the gene EP300 and Rubinstein-Taybi syndrome.